Acute Heart Failure (AHF) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032


 Acute heart failure (AHF) is the sudden onset or worsening of symptoms and signs associated with heart failure (HF). This critical condition typically requires hospitalization, focusing on the immediate management of fluid overload and compromised hemodynamics. It encompasses individuals experiencing typical HF symptoms and signs for the first time (de novo AHF) and those with exacerbated symptoms of their existing cardiomyopathy (acute decompensated heart failure). Heart failure (HF) is a clinical syndrome characterized by symptoms, including breathlessness, difficulty breathing while lying down, lower limb swelling, and signs such as elevated jugular vein pressure and lung congestion. These manifestations result from structural and functional abnormalities in the heart, leading to reduced cardiac output and increased pressures within the heart. More than 50% of patients in high-income regions and Eastern and Central European areas, acute heart failure admissions are primarily linked to ischemic heart disease. Globally, hypertension consistently contributes to the occurrence of heart failure. The most common HF symptoms include exertional or resting breathlessness, discomfort when lying flat (orthopnea), fatigue, and reduced exercise capacity. These symptoms are often accompanied by clinical signs such as limb swelling, distended jugular veins, a third heart sound called the "S3 gallop," and pulmonary rales. The European Society of Cardiology (ESC) classified heart failure patients into six groups based on their clinical presentations:

1.       Acute decompensated congestive heart failure involves worsening chronic heart failure, characterized by a gradual onset of peripheral edema and significant dyspnea.

2.       AHF with hypertension: This is marked by a rapid increase in systolic blood pressure, pulmonary congestion, tachycardia, preserved left ventricular ejection fraction (LVEF), and relatively low mortality.

3.       AHF with pulmonary edema: This presents with sudden or gradual severe respiratory distress, widespread lung rales, tachypnea, orthopnea, and arterial oxygen saturation (SaO2) below 90%.

4.       Cardiogenic shock: This is a highly fatal syndrome characterized by gradual or rapid organ and tissue hypoperfusion, reduced urine output, and systolic blood pressure below 90 mm Hg.

5.       AHF complicating acute coronary syndrome (ACS): This results from increased left ventricular diastolic filling pressure or decreased cardiac output due to myocardial ischemia or infarction.

6.       Isolated right-sided AHF: This is characterized by rapid or gradual edema onset, jugular vein distention, hepatomegaly, clear lungs, low blood pressure, reduced left ventricular filling pressure, and decreased cardiac output.

The first-line treatment for acute heart failure is loop diuretics. These drugs include furosemide, bumetanide, and torsemide.

·       The prevalence of heart failure is estimated to be 6 million individuals, approximately 1.8% of the US population.

Thelansis’s “Acute Heart Failure (AHF) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Acute Heart Failure (AHF) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Acute Heart Failure (AHF) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Acute Heart Failure (AHF) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Acute Heart Failure (AHF) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Metabolic syndrome refers to a clustering of multiple disorders that collectively increase an individual's susceptibility to atherosclerotic cardiovascular disease, insulin resistance, diabetes mellitus, as well as vascular and neurological complications such as cerebrovascular accidents. The underlying causes of metabolic syndrome typically include excess weight, obesity, a sedentary lifestyle, and genetic predisposition. This syndrome exerts detrimental effects on various body systems. Insulin resistance, a key component of metabolic syndrome, leads to microvascular damage, increasing the risk of endothelial dysfunction, vascular resistance, hypertension, and inflammation of vessel walls. Bariatric surgery is recognized as the most effective standalone therapy for metabolic syndrome. However, patients undergoing this procedure require long-term follow-up to mitigate potential surgical, nutritional, and psychiatric complications. Thelansis’s “Metabolic Syndrome Market Outl...
Read more

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Type 1 Diabetes Mellitus (T1D) is characterized as an autoimmune disorder resulting in the autoimmune destruction of insulin-producing pancreatic beta cells. This condition necessitates life-long insulin replacement, administered through multiple daily insulin injections, insulin pump therapy, or an automated insulin delivery system. The absence of insulin can lead to the development of Diabetic Ketoacidosis (DKA), a life-threatening condition. The most common symptoms associated with this disease are polyuria and polydipsia. Effective management of T1D involves: Multiple daily insulin injections Insulin pump therapy An automated insulin delivery system in conjunction with glucose monitoring Continuous Glucose Monitoring (CGM) is the preferred method. However, all individuals with T1D should be capable of performing Blood Glucose Monitoring (BGM) via capillary blood if CGM is not available. Acute complications of diabetes primarily include hypo...
Read more